CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population

Kapaki, E; Paraskevas, GP; Zalonis, I; Zournas, C

dc.contributor.author	Kapaki, E	en
dc.contributor.author	Paraskevas, GP	en
dc.contributor.author	Zalonis, I	en
dc.contributor.author	Zournas, C	en
dc.date.accessioned	2014-03-01T01:53:06Z
dc.date.available	2014-03-01T01:53:06Z
dc.date.issued	2003	en
dc.identifier.issn	1351-5101	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26853
dc.subject	ageing	en
dc.subject	Alzheimer's disease	en
dc.subject	beta-amyloid	en
dc.subject	dementia	en
dc.subject	Tau protein	en
dc.subject.classification	Clinical Neurology	en
dc.subject.classification	Neurosciences	en
dc.subject.other	CEREBROSPINAL-FLUID TAU	en
dc.subject.other	APOLIPOPROTEIN-E GENOTYPE	en
dc.subject.other	INTERNATIONAL WORKSHOP	en
dc.subject.other	BIOCHEMICAL MARKER	en
dc.subject.other	PATHOLOGICAL DIAGNOSIS	en
dc.subject.other	COGNITIVE IMPAIRMENT	en
dc.subject.other	PHOSPHORYLATED TAU	en
dc.subject.other	CLINICAL-DIAGNOSIS	en
dc.subject.other	VASCULAR DEMENTIA	en
dc.subject.other	LEWY BODIES	en
dc.title	CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2003	en
heal.abstract	Cerebrospinal fluid (CSF) levels of tau protein and amyloid beta (1-42) peptide (Abeta42) have been suggested as possible diagnostic markers of Alzheimer's disease (AD). In order to evaluate their diagnostic potential in clinical practice, we measured tau and Abeta42 levels in the CSF of 49 AD patients, 15 patients with non-AD neurodegenerative dementias (NAND), six patients with vascular dementia (VD) and 49 elderly controls. All the subjects were of Greek origin. A marked increase in tau, a decrease in Abeta42 and a marked increase in the tau/Abeta42 ratio was noted in AD. Abeta42 alone had a specificity of 80% and a sensitivity of 82% in differentiating AD from normal ageing, whilst the corresponding values for differentiating AD from NAND or VD were 80 and 71, or 67 and 82%, respectively. Tau was better in differentiating AD, from normal ageing (specificity 96%, sensitivity 88%), NAND (specificity 93%, sensitivity 71%) and VD (specificity 83%, sensitivity 94%). The tau/Abeta42 ratio achieved values comparable or even better than tau for differentiating AD from normal ageing (specificity 86%, sensitivity 96%) and VD (specificity 83%, sensitivity 90%) and definitely better than any of the candidate markers alone, for differentiating AD from NAND (specificity 100%, sensitivity 71%). Thus, the combined use of CSF tau and Abeta42 in the form of the tau/Abeta42 ratio is a simple, safe and useful adjuvant to clinical criteria for dementia diagnosis.	en
heal.publisher	BLACKWELL PUBLISHING LTD	en
heal.journalName	EUROPEAN JOURNAL OF NEUROLOGY	en
dc.identifier.isi	ISI:000181229800001	en
dc.identifier.volume	10	en
dc.identifier.issue	2	en
dc.identifier.spage	119	en
dc.identifier.epage	128	en